SK Bioscience Co Ltd (302440)

Currency in KRW
43,350
-2,400(-5.25%)
Closed·

302440 Financial Summary

Key Ratios

P/E Ratio-73.95
Price/Book1.97
Debt / Equity19.76%
Return on Equity-2.17%
Dividend Yield0.00%
EBITDA-89.21B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of KRW (except for per share items)

Analyst Ratings

0 Buy
2 Hold
3 Sell
Ratings:
5 analysts
Overall Consensus
Sell

Analysts 12-Month Price Target:

Average 36,000
(-16.96% Downside)

Earnings

Latest Release
Jul 31, 2025
EPS / Forecast
-199.73 / -323.89
Revenue / Forecast
131.00B / 143.00B
EPS Revisions
Last 90 days

FAQ

What were SK Bioscience Co's earnings for the latest quarter?

The SK Bioscience Co EPS (TTM) is -613.92. SK Bioscience Co reported sales of 154,557.72, net income of -7,465.65, and EPS of -199.73 for the latest quarter.

What was SK Bioscience Co's net income for the latest quarter?

SK Bioscience Co's net income for the latest quarter was -7,465.65.

How did SK Bioscience Co's performance compare year-over-year in the latest quarter?

The company's revenue moved from 156,849.23 in the previous quarter to 154,557.72 in the latest quarter, and net income moved from -6,437.12 to -7,465.65 compared to the previous quarter.

What is SK Bioscience Co's net profit margin on a TTM basis?

SK Bioscience Co's trailing twelve months (TTM) net profit margin is -20.14%.

How does SK Bioscience Co's debt to equity ratio compare to industry standards?

SK Bioscience Co's total debt-to-equity ratio is 19.76%.

What is SK Bioscience Co's return on investment on a TTM basis?

SK Bioscience Co's trailing twelve months (TTM) return on investment (ROI) is -2.17%.

Did SK Bioscience Co gain or lose cash last quarter?

In the latest quarter, SK Bioscience Co's net change in cash was -6,957.55 million.

What were SK Bioscience Co's total assets and liabilities in the latest quarter?

As of the latest quarter, SK Bioscience Co reported total assets of 2,902,103.02 million and total liabilities of 347,565.42 million.

How has SK Bioscience Co's total revenue grown this year?

SK Bioscience Co's total revenue was 156,849.23 in the previous quarter and 154,557.72 in the latest quarter.

What is SK Bioscience Co's gross margin on a TTM basis?

SK Bioscience Co's trailing twelve months (TTM) gross margin is 12.69%.

What was SK Bioscience Co's revenue per share for the latest quarter?

SK Bioscience Co's revenue per share for the latest quarter was 14,147.89.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.